In preclinical mouse models, YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated CAR as tisagenlecleucel, exhibited enhanced in vivo expansion and antitumor activity at lower doses than traditionally manufactured CAR T-cells.
[Cancer Discovery]